Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Convertible Debt (2016 - 2021)

Rocket Pharmaceuticals' Convertible Debt history spans 6 years, with the latest figure at $35.5 million for Q1 2021.

  • For Q1 2021, Convertible Debt fell 22.38% year-over-year to $35.5 million; the TTM value through Mar 2021 reached $35.5 million, down 22.38%, while the annual FY2020 figure was $35.1 million, 22.16% down from the prior year.
  • Convertible Debt for Q1 2021 was $35.5 million at Rocket Pharmaceuticals, up from $35.1 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $49.4 million in Q3 2017 and bottomed at $35.1 million in Q4 2020.
  • The 5-year median for Convertible Debt is $42.7 million (2019), against an average of $43.0 million.
  • The largest annual shift saw Convertible Debt rose 8.69% in 2019 before it decreased 22.38% in 2021.
  • A 5-year view of Convertible Debt shows it stood at $49.4 million in 2017, then decreased by 16.08% to $41.4 million in 2018, then rose by 8.69% to $45.0 million in 2019, then decreased by 22.16% to $35.1 million in 2020, then grew by 1.36% to $35.5 million in 2021.
  • Per Business Quant, the three most recent readings for RCKT's Convertible Debt are $35.5 million (Q1 2021), $35.1 million (Q4 2020), and $42.1 million (Q3 2020).